Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy

Cardiovascular Research

Volumn 100, Issue 1, 2013, Pages 63-73

  Kannan, Sankaranarayanan ^a,b   Muthusamy, Vasanthi R ^a   Whitehead, Kevin J ^a   Wang, Li ^a   Gomes, Aldrin V ^c   Litwin, Sheldon E ^d   Kensler, Thomas W ^e   Abel, E Dale ^a   Hoidal, John R ^a   Rajasekaran, Namakkal S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Cardiomyopathy; Nrf2; Protein aggregation; Reductive stress

Indexed keywords

CHAPERONE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE DISRUPTION; HEART FAILURE; HOMEOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TAKOTSUBO CARDIOMYOPATHY; TRANSGENIC MOUSE;

ANTIOXIDANTS; CARDIOMYOPATHY; NRF2; PROTEIN AGGREGATION; REDUCTIVE STRESS;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; ENDOPLASMIC RETICULUM STRESS; GLUTATHIONE; HOMEOSTASIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; STRESS, PHYSIOLOGICAL; UBIQUITINATION;

EID: 84887935144     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt150     Document Type: Article

References (40)

1. Lloyd-Jones D., Adams R, Carnethon M., De Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2009; 119: 480-486.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin E.J., Berry JD, Borden WB et al. American Heart Association Statistics C, Stroke Statistics S. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.
3. Spirito P, Seidman CE, McKenna W.J., Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.
4. Maron BJ, Gardin JM, Flack J.M., Gidding SS, Kurosaki TT, Bild DE. Prevalence of hyper-trophic cardiomyopathy ina general population of young adults. Echocardiographic analysis of 4111 subjects in the cardia study. Coronary artery risk development in (young) adults. Circulation 1995; 92: 785-789.
5. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995; 91: 1596-1601.
6. Delbosc S, Paizanis E, Magous R., Araiz C, Dimo T, Cristol JP et al. Involvementofoxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 2005; 179: 43-49.
7. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115: 500-508.
8. Takimoto E, Champion HC, Li M, Ren S., Rodriguez ER, Tavazzi B et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005; 115: 1221-1231.
9. Rajasekaran NS, Sathyanarayanan S, Devaraj N.S., Devaraj H. Chronic depletion of gluta-thione (gsh) and minimal modification of ldl in vivo: Its prevention by glutathione mono ester (gme) therapy. Biochim Biophys Acta 2005; 1741: 103-112.
10. Rajasekaran NS, Connell P, Christians E.S., Yan LJ, Taylor RP, Orosz A et al. Human alpha b-crystallin mutation causes oxido-reductive stress and protein aggregation cardiomy-opathy in mice. Cell 2007; 130: 427-439.
11. Martensson J, Jain A, Stole E., Frayer W, Auld PA, Meister A. Inhibition of glutathione synthesis in the newborn rat: a model for endogenously produced oxidative stress. Proc Natl Acad Sci USA 1991; 88: 9360-9364.
12. Meister A. Glutathione deficiency produced by in hibitionofits synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 1991; 51: 155-194.
13. Rajasekaran NS, Varadharaj S, Khanderao G.D., Davidson CJ, Kannan S, Firpo MA et al. Sustained activation of nuclear erythroid 2-related factor 2/antioxidant response element signaling promotes reductive stress in the human mutant protein aggregation cardiomyopathy in mice. Antioxid Redox Signal 2011; 14: 957-971.
14. Copple IM, Goldring CE, Kitteringham N.R., Park BK. The keap1-nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity. Handb Exp Pharmacol 2010; 233-266.
15. Rangasamy T, Cho CY, Thimmulappa R.K., Zhen L., Srisuma SS, Kensler TW et al. Genetic ablation of nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004; 114: 1248-1259.
16. Li J, Ichikawa T, Villacorta L., Janicki JS, Brower GL, Yamamoto M et al. Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol 2009; 29: 1843-1850.
17. Russell RL, Siedlak SL, Raina A.K., Bautista JM, Smith MA, Perry G. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in alzheimer disease. Arch Biochem Biophys 1999; 370: 236-239.
18. Gounder SS, Kannan S, Devadoss D., Miller CJ, Whitehead KS, Odelberg SJ et al. Impaired transcriptional activity of nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training. PLoS One 2012; 7:e45697.
19. Muthusamy VR, Kannan S, Sadhaasivam K., Gounder SS, Davidson CJ, Boeheme C et al. Acute exercise stress activates nrf2/are signaling and promotes antioxidant mechanisms in the myocardium. Free Radic Biol Med 2012; 52: 366-376.
20. Bader FM, Islam N, Mehta N.A., Worthen N., Ishihara S, Stehlik J et al. Noninvasive diag-nosis of cardiacallograft rejection using echocardiography indices of systolic and diastolic function. Transplant Proc 2011; 43: 3877-3881.
21. Symons JD, Hu P, Yang Y., Wang X, Zhang QJ, Wende AR et al. Knockout of insulin receptors in cardiomyocytes attenuates coronary arterial dysfunction induced by pressure overload. Am J Physiol Heart Circ Physiol 2011; 300:H374-H381.
22. Miller CJ, Gounder SS, Kannan S, Goutam K., Muthusamy VR, Firpo MA et al. Disruption of nrf2/are signaling impairs antioxidant mechanisms and promotes cell degradation pathways in aged skeletal muscle. Biochim Biophys Acta 2012; 1822: 1038-1050.
23. Rajasekaran NS, Firpo MA, Milash B.A., Weiss RB, Benjamin IJ. Global expression profiling identifies a novel biosignature for protein aggregation r120gcryab cardiomyopathy in mice. Physiol Genomics 2008; 35: 165-172.
24. Rangasamy T, Guo J, Mitzner W.A., Roman J., Singh A, Fryer AD et al. Disruption of nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 2005; 202: 47-59.
25. Finley D. Recognition and processing of ubiquitin-protein conjugatesby the proteasome. Ann Rev Biochem 2009; 78: 477-513.
26. Abel ED, Doenst T. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc Res 2011; 90: 234-242.
27. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010; 128: 191-227.
28. Drozdov I, Tsoka S, Ouzounis C.A., Shah AM. Genome-wide expression patterns in physiological cardiac hypertrophy. BMC Genom 2010; 11: 557.
29. Song HK, Hong SE, Kim T, Kim do H. Deep RNA sequencing reveals novel cardiac tran-scriptomic signatures for physiological and pathological hypertrophy. PloS One 2012; 7: e35552.
30. Ishii T, Itoh K, Yamamoto M. Roles of nrf2 in activation of antioxidant enzyme genes via antioxidant responsive elements. Methods Enzymol 2002; 348: 182-190.
31. Itoh K, Wakabayashi N, Katoh Y., Ishii T, O'Connor T, Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of nrf2inresponse to electrophiles. Genes Cells 2003; 8: 379-391.
32. Trotter EW, Grant CM. Thioredoxins are required for protection against a reductive stress in the yeast Saccharomyces cerevisiae. Mol Microbiol 2002; 46: 869-878.
33. Lipinski B. Evidence in support of aconcept of reductive stress. Br J Nutr 2002; 87: 93-94.
34. Dimmeler S, Zeiher AM. A 'reductionist' view of cardiomyopathy. Cell 2007; 130: 401-402.
35. Hermann J, Gulati R, Napoli C., Woodrum JE et al. Oxidative stress-related increase in ubiquitination in early coronary atherogenesis. FASEB J 2003; 17: 1730-1732.
36. Gu Z, Nakamura T, Yao D., Shi ZQ, Lipton SA. Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson's disease. Cell Death Diff 2005; 12: 1202-1204.
37. Hwang C, Sinskey AJ, Lodish HF. Oxidized redox state of glutathione in the endoplasmic reticulum. Science 1992; 257: 1496-1502.
38. Appenzeller-Herzog C. Glutathione- and non-glutathione-based oxidant control in the endoplasmic reticulum. J Cell Sci 2011; 124: 847-855.
39. Jung T, Bader N, Grune T. Oxidized proteins: intracellular distribution and recognition by the proteasome. Arch Biochem Biophys 2007; 462: 231-237.
40. Willis MS, Townley-Tilson WH, Kang E.Y., Homeister JW, Patterson C. Sent to destroy: The ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res 2010; 106: 463-478.